Core Laboratories (CLB) officer reports restricted stock vesting and 340-share sale

Rhea-AI Filing Summary

Core Laboratories Inc. CAO & Treasurer reported equity transactions in company stock dated 12/01/2025. The officer had 864 restricted shares convert into common stock at a price of $0, increasing directly held common shares to 8,765.334.

To cover obligations associated with this vesting, 340 common shares were disposed of at $15.39 per share, leaving the officer with 8,425.334 shares before the conversion and 8,765.334 afterward. The filing also shows 6,690 restricted shares remaining, from multiple grants that vest annually over six years as long as the officer continues in service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teo Sow Hang

(Last) (First) (Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON TX 77040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CAO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		F		340	D	$15.39	8,425.334	D
Common Stock	12/01/2025		M		864	A	$0	8,765.334	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Shares	(1)	12/01/2025		M			864	(1)	(1)	Common Stock	864	$0	6,690(2)	D

Explanation of Responses:

1. The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date.

2. Multiple restricted share grants are included in this total.

	/s/ Mark Tattoli, Attorney-in-Fact	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Core Laboratories (CLB) report for its CAO & Treasurer?

The CAO & Treasurer of Core Laboratories Inc. (CLB) reported a vesting and conversion of 864 restricted shares into common stock on 12/01/2025, along with related share disposals.

How many Core Laboratories shares did the officer acquire and at what price?

The officer acquired 864 shares of common stock from restricted shares at a price of $0 per share, reflecting the vesting of equity awards rather than an open-market purchase.

How many Core Laboratories shares were disposed of in this transaction?

The officer disposed of 340 shares of Core Laboratories common stock at a price of $15.39 per share in connection with the reported transaction.

What is the officer’s Core Laboratories common stock holding after the reported transactions?

Following the reported transactions, the officer directly holds 8,765.334 shares of Core Laboratories common stock.

How many restricted shares of Core Laboratories does the officer still hold?

After the vesting event, the officer beneficially owns 6,690 restricted shares of Core Laboratories, representing multiple restricted share grants.

How do the Core Laboratories restricted shares vest for this officer?

The restricted shares vest annually over six years on the grant date anniversary, in amounts set in the award agreement, as long as the officer remains in continuous service on each vesting date.